HOPA Annual Conference 2024
Patients with a history of venous thromboembolism were more likely to receive VTE prophylaxis.
Patients ≥70 years of age were more likely to have a reduction in their palbociclib dosage.
Rates of treatment-related hypersensitivity reactions were low in an academic community setting.
Same-day administration of pegfilgrastim was not linked to a greater incidence of grade ≥3 neutropenia.
Lenvatinib plus pembrolizumab led to a clinically relevant response in patients with baseline metastasis.
Higher average talazoparib concentrations were associated with an increased risk of severe anemia and thrombocytopenia.
Decreasing the at-home dose of dexamethasone before paclitaxel treatment may help reduce the incidence of infusion reactions.
Protected administrative time was ranked as the most important change to improve well-being.
Ibrutinib dose reductions were associated with fewer recurrent cardiac adverse events in patients with B-cell malignancies.
The REMEDY trial evaluated remote continuous temperature monitoring in patients receiving cytotoxic chemotherapy.
PTCy/Tac/MMF and tacrolimus plus methotrexate provided similar rates of graft-versus-host disease prevention.
Cemiplimab plus chemotherapy as a first-line treatment for advanced NSCLC led to improved survival.
Advertisement
Advertisement
